Il laboratorio: verso una migliore definizione dei test
|
|
- Roy Barber
- 5 years ago
- Views:
Transcription
1 Il laboratorio: verso una migliore definizione dei test Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University of Milano
2 Laboratory & DOAC When to measure DOAC reach (Cmax) approximately 2 hours after ingestion DOAC reach Ctrough approximately 12h (bid) or 24h (od) after ingestion Timing of blood draw is essential for results interpretation
3 Which Test for Dabigatran APTT Thrombin Time (TT) PT INR Ecarin clotting time (ECT) Anti FIIa activity
4 APTT & Dabigatran Van Ryn et al, 2010
5 Commercial APTT & Dabigatran Hawes EM et al, 2013
6 ECT & Dabigatran Van Ryn et al, 2010
7 Stangier et al, 2007
8 Van Ryn et al, 2010
9 Which Test for Rivaroxaban Anti Xa PT APTT HepTest dilute Russell Viper Venom Time (drvvt) Others (whole blood monitors, TG, etc.)
10 Rivaroxaban Prothrombin Time
11 Corresponding to 20 mg once daily Samama et al, 2010
12 Order of thromboplastin responsiveness to rivaroxaban Thromboplastin Neoplastin Plus Recombiplastin Neoplastin Triniclot Thromborel S Innovin et al. JTH 2011 Riva SI
13 Between-thromboplastin variability according to results expression A. Tripodi et al, JTH 2011 CV% CV=29.6% CV=14.0% CV=2.1% PT-ratio INR Riva-PT-ratio
14 Which Test for Apixaban Anti FXa APTT PT Others A. Tripodi
15 Apixaban & PT (Douxifils et al, 2013)
16 Apixaban & Anti Fxa (Douxifils et al, 2013)
17 Alternatives for PT (and other tests) Standardization
18 Clotting time Normal plasma + Drug at increasing concentration Drug Concentration
19 clotting times for calibration plasmas depend on: Pro-coagulant activity of the normal plasma plus The effect of the drug
20 normal plasmas are not equal in terms of procoagulant activity
21 Clotting time Normal plasma 1 Normal plasma 2 Drug Concentration
22 Expected Therapeutic Dabigatran Concentrations Peak 175 ng/ml ( ) Trough 91 ng/ml (61 143)
23 Expected Therapeutic Rivaroxaban Concentrations Peak 215 ng/ml (22 535) Trough 32 ng/ml (6 239)
24 Expected Therapeutic Apixaban Concentrations Peak 162 ng/ml (range??) Trough 19 ng/ml (range??)
25 Conclusions (1) How to measure the effect of Dabigatran Dilute TT or ECT Ratio (patient/normal) Results Expression Drug concentration from calibration curve
26 Conclusions (2) How to measure the effect of Rivaroxaban anti-fxa or PT Results expression Anti-FXa - Drug concentration from calibration curve PT - Ratio (patient/normal) - No INR - Riva-PT-ratio is an alternative
27 Conclusions (3) How to measure the effect of Apixaban Anti-FXa Results expression Anti-FXa - Drug concentration from calibration curve
28 Conclusions (4) Usefulness of measuring the effect of DOAC Useful - At baseline (before initiation of treatment) - Before surgical/invasive procedures - Adverse events (hemorrhage or thrombosis) - Need for reversal of anticoagulation Potentially useful - When chronic anticoagulation is achieved (1-2 weeks after initiation) - At regular intervals during clinical visits - Soon before and after introducing additional drugs - Extreme body weight
29 Cosa fare subito Attrezzarsi prima possibile con i test consigliati Valutare il comportamento dei test di base (PT, APTT) mediante la loro esecuzione su plasmi calibranti a titolo noto del farmaco Organizzare riunioni aziendali con tutti i soggetti coinvolti, per stabilire linee di comportamento condivise In una prima fase eseguire alla bisogna test specifici ma anche di base per capire meglio il loro comportamento
30 Antidotes & Reversal
31
32
33
34 Circulation 2011; 124 : Conclusions PCC immediately and completely reverses the effect of rivaroxaban, but has no influence on dabigatran when assessed by lab tests
35 Rivaroxaban & PT Placebo PCC
36 Dabigatran & thrombin time Placebo PCC
37 If different DOAC have different antidote/reversal strategy Knowledge of the drug being taken by patients is essential for management of reversal
38 DOAC effect of the most common hemostatic parameters Antithrombin Fibrinogen APC resistance Factor assay Protein C anticoagulant activity Protein S anticoagulant activity Lupus anticoagulant Factor XIII
39 Conclusions Although DOAC do not require doseadjustment based on lab testing, assessment of their anticoagulant effect is useful in many circumstances Caution should be exerted when interpreting results of hemostatic parameters in patients taking DOAC
40 Blood 2013;121:4032-5
New Anticoagulants: Laboratory Monitoring?? Dr Steve Kitchen Sheffield Haemostasis and Thrombosis centre UK
New Anticoagulants: Laboratory Monitoring?? Dr Steve Kitchen Sheffield Haemostasis and Thrombosis centre UK Ideal Anticoagulant (Hirsh et al 2004) High efficacy to safety ratio Predictable dose response
More informationlaboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie.
laboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie. Disclosures Malake Naboulsi declare to meeting attendees that
More informationLaboratory Monitoring Measurement of the DOACs
1 Laboratory Monitoring Measurement of the DOACs ACC Anticoagulation Consortium Roundtable Meeting October 24, 2015 Adam Cuker, MD, MS Perelman School of Medicine University of Pennsylvania 2 Full disclosures
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationBLOOD DISEASE RESEARCH FOUNDATION
BLOOD DISEASE RESEARCH FOUNDATION BLOOD DISEASE RESEARCH FOUNDATION The mission of Blood Disease Research Foundation is to support hematological research, e.g. by donating grants for thesis work and abstract
More informationMonitoraggio di laboratorio dei NOA: NO
Monitoraggio di laboratorio dei NOA: NO Daniela Poli Firenze Vietri 8 Ottobre 2016 Ruff C, Lancet 2013 Stroke or systemic embolic events Dabigatran 150 mg bid Rivaroxaban 20 mg od Apixaban 5 mg bid Edoxaban
More informationMEASUREMENT OF ANTICOAGULANT EFFECTS OF NEW ORAL ANTICOAGULANTS PRACTICAL ASPECTS
MEASUREMENT OF ANTICOAGULANT EFFECTS OF NEW ORAL ANTICOAGULANTS PRACTICAL ASPECTS Désirée Coen Herak Department of Laboratory Diagnostics University Hospital Centre Zagreb WARFARIN ERA Warfarin monopoly
More informationManaging Bleeding in the Patient on DOACs
Managing Bleeding in the Patient on DOACs Spring 2016 Jean M. Connors, MD Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine, HMS Conflicts
More informationFeedback from the EMA
Feedback from the EMA Jens Heisterberg, MD Danish Medicines Agency Is There a Role For Pharmacokinetic/Pharmacodynamics Guided Dosing For Novel Anticoagulants? CSRC Meeting, Washington D.C., December 3,
More informationMonitoring target-specific oral anticoagulants
NONTRADITIONAL LABORATORY ASSAYS OF HEMOSTASIS:WHAT THE CONSULTING HEMATOLOGIST SHOULD KNOW Monitoring target-specific oral anticoagulants Barbara A. Konkle 1,2 1 Hemostasis Reference Laboratory, Puget
More informationLaboratory monitoring of oral anticoagulants. A/Prof. Lee Lai Heng Haematology Singapore General Hospital
Laboratory monitoring of oral anticoagulants A/Prof. Lee Lai Heng Haematology Singapore General Hospital Relevant Disclosures Educational and Travel Grants Bayer, Leo, Bristol Meyer Squib Advisory Boards
More informationÈ possibile cambiare posologia o farmaco sulla base dei test di laboratorio?
È possibile cambiare posologia o farmaco sulla base dei test di laboratorio? Armando D Angelo Servizio di Coagulazione ed Unità Ricerca Trombosi, IRCCS Ospedale San Raffaele, Milano XXVI CONGRESSO NAZIONALE
More informationCOAGULATION TESTING AND NEW ORAL ANTICOAGULANTS
COAGULATION TESTING AND NEW ORAL ANTICOAGULANTS SOPHIE TESTA Haemostasis and Thrombosis Center ASST-Cremona, Italy ANTICOAGULANT DRUGS Eikelboom JW, Weitz JI. Circulation 2010;6:1523-32 DRUGS UH LAB aptt
More informationL iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche
L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University
More informationInsights on the Quality of Coagulation Testing
Insights on the Quality of Coagulation Testing Piet Meijer ECAT Foundation The Netherlands No conflicts of interest HAEMOSTATIC BALANCE BLEEDING HAEMOSTATIC BALANCE THROMBOSIS HAEMOSTATIC BALANCE Thrombosis
More informationOral Factor Xa Inhibitors and Clinical Laboratory Monitoring
Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.
More informationWorldwide Report Coagulation Lot Exp 31 Oct 2018
April 0 Worldwide Report Coagulation Lot 780 Exp Oct 08 Activated Partial Thromboplastin Time (APTT) Diagnostica Stago C.K. Prest Seconds 0.7 0.89.8 9 0.7 0.89.8 9 8.8..7 8.8..7 9.90 0.97.0 9.90 0.97.0
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationPICT ANTICOAGULANT MONITORING 1. PEFAKIT PICT. Clotting Assay. PEFAKIT PiCT. PEFAKIT PICT Calibrators UFH. PEFAKIT PICT Controls UFH
1 2 3 4 PEFAKIT PiCT PEFAKIT PICT Calibrators UFH PEFAKIT PICT Controls UFH PEFAKIT PICT Calibrators LMWH Clotting Assay PICT 1. PEFAKIT PICT Package size 8-505-01 kit 80 3 vials of PiCT Activator (2mL)
More informationAndexanet Alfa: Reversal agent for FXa Inhibitors
Andexanet Alfa: Reversal agent for FXa Inhibitors Grace Gilmore, Prof Ross Baker, Dr Jim Tiao, Dr Quintin Hughes, Dr Jasmine Tay, Scott McGregor WA Centre for Thrombosis and Haemostasis, Murdoch University,
More information3/25/2016. Objectives for Pharmacists. Stop the Bleeding! New Reversal Agents. Objectives for Pharmacy Technicians. Assessment Pre-test
Objectives for Pharmacists Stop the Bleeding! New Reversal Agents Gary D Peksa, Pharm.D., BCPS Clinical Pharmacy Specialist, Emergency Medicine Rush University Medical Center Review current strategies
More informationThe effect of the direct oral anticoagulants (DOACs) on haemostasis tests.
The effect of the direct oral anticoagulants (DOACs) on haemostasis tests. Emmanuel J Favaloro, Haematology, ICPMR, Pathology West, Sydney Centres for Thrombosis and Haemostasis, Westmead Hospital (with
More informationManaging Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants
Managing Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants MICHAEL E. MULLINS MD FAACT FACEP Washington University School Of Medicine Chair, BJH Anticoagulation Subcommittee Chair,
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationNew and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationReversal Agents and Peri-procedural Management
Contemporary Approach to Anticoagulation Management Reversal Agents and Peri-procedural Management Alawi A. Alsheikh-Ali, MD, MSc College of Medicine Mohammed Bin Rashid University of Medicine and Health
More informationseminaires iris Mon patient prend un NACO, comment évaluer sa coagulation au Service des Urgences?
Mon patient prend un NACO, comment évaluer sa coagulation au Service des Urgences? Jonathan DOUXFILS, Department of pharmacy Faculty of Medicine University of Namur Séminaire IRIS Content Introduction
More informationUse of Anticoagulant Reversal Agents
Use of Anticoagulant Reversal Agents Lori Shutter, MD shutterla@upmc.edu Vice Chair of Education Director, Neurocritical Care Program Professor, Critical Care Medicine, Neurology & Neurosurgery University
More informationAnticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
More informationEmergency Management of Patients on Direct Oral Anticoagulants (DOACs)
Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October
More informationPharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics
Italian Journal of Medicine 2013; volume 7(s8):1-7 Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics Luca Masotti, 1 Mauro Campanini 2 1 Internal Medicine,
More informationNew drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle
New drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle CONCLUSIONS 1. Arrival of new anticoagulants is a Good Thing. CONCLUSIONS 1. Arrival of new anticoagulants
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationOverview of anticoagulants David Perry
Chapter 2 Overview of anticoagulants David Perry Historically anticoagulation involved the use of heparin and its derivatives or warfarin. However, the past few years have seen the introduction of a number
More informationOttobre 2016 Palazzo Bonin Longare Vicenza
10-11-12 Ottobre 2016 Palazzo Bonin Longare Vicenza Terapia an)coagulante orale: tra1amento delle complicanze emorragiche Vi#orio Pengo Clinica Cardiologica Università di Padova POTENTIAL PROBLEMS WITH
More informationREVERSAL STRATEGIES FOR ORAL ANTICOAGULATION
REVERSAL STRATEGIES FOR ORAL ANTICOAGULATION Wesley R. Zemrak, Pharm.D., BCPS Clinical Pharmacy Specialist, Anticoagulation Maine Medical Center, Portland, ME zemraw@mmc.org 1 OBJECTIVES 1. Discuss the
More informationA place for new oral anticoagulants in medicine: a fast evolving story
A place for new oral anticoagulants in medicine: a fast evolving story Prof Beverley Hunt MB ChB, FRCP, FRCPath, MD Chair of Thrombosis & Haemostasis, King s College, London Medical Director of Lifeblood:
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationIdarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):
Idarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):511-520. Objective: To measure the safety of idarucizumab to reverse dabigatran anticoagulant effects
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationNew Anticoagulants Monitoring or Not Monitoring?
New Anticoagulants Monitoring or Not Monitoring? For monitoring M.M. Samama, C. Guinet, L. Le Flem, J. Conard Hôtel-Dieu-Cochin University Hospital (Paris, France) and Biomnis, Ivry sur Seine, France Disclosure
More informationLa gestione dell anticoagulazione orale
La gestione dell anticoagulazione orale Armando D Angelo Servizio di Coagulazione & Unità Ricerca Trombosi IRCCS Ospedale San Raffaele, Milano, Italia 1 Corso SISET Cremona 20 settembre 2016 Warfarin Narrow
More informationChallenges in Coagulation
Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from
More informationCoagulation BEFORE Surgery
Coagulation BEFORE Surgery Lorenzo ALBERIO Médecin chef Hématologie générale et Hémostase Service et Laboratoire centrale d Hématologie CHUV, Lausanne Outline 1. Pre-op testing 2. Ongoing anticoagulation
More informationStolling en anesthesie. Erik Vandermeulen MD, PhD Dept. of Anesthesia
Stolling en anesthesie Erik Vandermeulen MD, PhD Dept. of Anesthesia Preoperative use of anticoagulation Vitamin K-antagonists (VKA) Fenprocoumon (Marcoumar ) Warfarin (Marevan ) Acenocoumarol (Sintrom
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationLa gestione dell ictus ischemico o emorragico nel paziente sotto NAO
La gestione dell ictus ischemico o emorragico nel paziente sotto NAO Antonio Carolei e Cindy Tiseo Clinica Neurologica e Stroke Unit Avezzano - Sulmona Università degli Studi dell Aquila Abano Terme, 10
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationNEW ORAL ANTICOAGULANTS: A VIEW FROM THE LABORATORY
NEW ORAL ANTICOAGULANTS: A VIEW FROM THE LABORATORY Jing Jin Clinical laboratory Scientist (MLS, ASCP) - Coagulation/Hematology Stanford University Hospital and Clinics 1 OBJECTIVES 1. Describe the mechanisms
More informationUse of Prothrombin Complex Concentrates (PCC) CONTENTS
CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis
More informationHEMOSTASIS Quality Time saving Economy Practicability Quality assurance Precision
Quality Time saving Economy Practicability Quality assurance Precision exclusive distributor of for France, Netherlands, Belgium and Luxembourg List of frozen reagents In 1992, Precision BioLogic began
More informationManaging Bleeding on NOACs
Managing Bleeding on NOACs and Other Evolving ED Protocols Objectives Understand that NOACs are widely used in clinical practice Discuss the new and evolving protocols for managing bleeding in patients
More informationComparison of Samples Obtained From 3.2% Sodium Citrate Glass and Two 3.2% Sodium Citrate Plastic Blood Collection Tubes Used in Coagulation Testing
Coagulation and Transfusion Medicine / GLASS VS PLASTIC IN HEMOSTASIS TESTING Comparison of Samples Obtained From 3.2% Sodium Citrate Glass and Two 3.2% Sodium Citrate Plastic Blood Collection Tubes Used
More informationCoagulation, Haemostasis and interpretation of Coagulation tests
Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationEliquis effect on inr prolongation 2017
Eliquis effect on inr prolongation 2017 The Borg System is 100 % Eliquis effect on inr prolongation 2017 Dec 17, 2016. Clin Chem Lab Med 2017; 55(8): e178 e180. Letter to the Editor. Tuukka A. Helin. prolongs
More informationContent 1. Relevance 2. Principles 3. Manangement
Intracranial haemorrhage and anticoagulation Department of Neurology,, Germany Department of Neurology, Heidelberg University Hospital, Germany Department of Clinical Medicine Copenhagen University, Denmark
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationReversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately
More informationInteractive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome)
Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome) Ara Metjian, MD Duke Debates Benign Hematologic Highlights April 22, 2017 Disclaimer
More informationReversal of DOACs Breakthroughs and Their Aftermath
Reversal of DOACs Breakthroughs and Their Aftermath Geno J Merli, MD, MACP, FSVM, FHM Professor Medicine & Surgery Co-Director Jefferson Vascular Center Sidney Kimmel Medical College Thomas Jefferson University
More informationReversal of Oral Anticoagulation in Critical Care. Andrew C. Faust, PharmD, BCPS Critical Care Pharmacy Specialist Texas Health Presbyterian Dallas
Reversal of Oral Anticoagulation in Critical Care Andrew C. Faust, PharmD, BCPS Critical Care Pharmacy Specialist Texas Health Presbyterian Dallas Conflicts of Interest No conflicts to report Objectives
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationM B Garvey. University of Toronto
Do I really need that test??? M B Garvey Professor Emeritus University of Toronto St Michael s Hospital No relevant conflicts of interest 1 HEMOSTASIS IS LIKE LOVE Everybody talks about it, nobody understands
More informationGuidelines for testing and perioperative management of dabigatran and rivaroxaban
Guidelines for testing and perioperative management of dabigatran and rivaroxaban: for possible use in local management protocols These guidelines have been produced by PHARMAC in conjunction with bpac
More informationReversal of Direct Oral Anticoagulants. Why are we now seeing so many patients on DOACs? Objectives. DOAC: Recurrent VTE. DOAC: Intracranial Bleeding
Reversal of Direct Oral Anticoagulants Cameron D Griffiths, MD, FRCPC Clinical Assistant Professor Division of Hematology UBC Objectives Review efficacy and safety data for Direct Oral Anticoagulants (DOACs)
More informationOptimal Utilization of Thrombophilia Testing
Optimal Utilization of Thrombophilia Testing Rajiv K. Pruthi, MBBS Special Coagulation Laboratory & Comprehensive Hemophilia Center Division of Hematology/Internal Medicine Dept of Laboratory Medicine
More informationCurrent Practice in Emergency Management
Current Practice in Emergency Management Bundarika Suwanawiboon, MD Division of Hematology Department of Medicine Faculty of Medicine Siriraj Hospital Are you ready? www.techtimes.com, www.webmd.com Outline
More informationLupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid
, Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update William L. Nichols, MD Mayo Clinic College of Medicine Rochester, Minnesota USA Disclosures & Objectives (Nichols) Disclosures Relevant
More informationIntroduction. Blood Pressure
Introduction Spontaneous intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality worldwide [1]. Of a number of factors that have been linked to ICH (e.g., higher rates in Asians and
More informationNovel Anticoagulants: Emerging Evidence
18/10/2016 Topics: Novel Anticoagulants: Emerging Evidence Dr Matthew Swale Electrophysiologist Genesis Care NOAC Novel Oral Anti Coagulant Now Non-Vit K Oral Anti Coagulant DOAC Direct Oral Anti Coagulant
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationManagement of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents
Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist
More informationEverything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science
Everything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science Center at San Antonio Department of Pharmacotherapy
More informationChoosing and Managing Direct Oral Anticoagulants (DOACs)
Choosing and Managing Direct Oral Anticoagulants (DOACs) Ana G. Antun, MD, MSc Assistant Professor, Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University 1 Outline
More informationReversal of Action: Addressing the Unmet Need for Universal Antidotes to Factor Xa Anticoagulants. Disclosures
Reversal of Action: Addressing the Unmet Need for Universal Antidotes to Factor Xa Anticoagulants Daniel Pallin, MD, MPH Harvard Medical School Brigham and Women s Hospital Boston, Massachusetts Disclosures
More informationKeywords: anticoagulants, blood coagulation, blood coagulation tests, coagulation, dabigatran, drug monitoring. Introduction
Journal of Thrombosis and Haemostasis, : 49 50 DOI: 0./jth.08 ORIGINAL ARTICLE Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationNew Options for Anticoagulation Reversal: A Practical Approach
New Options for Anticoagulation Reversal: A Practical Approach Hyung Wook Park Chonnam National University Hospital, Gwangju, Korea 4 NOACs Prevention of TE No. of events (%/yr..) NOAC Warfarin HR 95%
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationHEMATOLOGY AND COAGULATION ANALYTIC PROTOCOLS
1 of 6 Policy #: 800 (PLH-800-13) Initiated Date: 12/4/2002 Reviewed Date: 8/1/2016 Subject: HEMATOLOGY AND COAGULATION ANALYTIC PROTOCOLS Approved by: Laboratory Director, Jerry Barker (electronic signature)
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationDr Tina Biss Consultant Haematologist Newcastle Hospitals NHS Foundation Trust. North East RTC Annual Education Symposium 16 th October 2014
Dr Tina Biss Consultant Haematologist Newcastle Hospitals NHS Foundation Trust North East RTC Annual Education Symposium 16 th October 2014 The extent of the problem 1-2% of the UK population are anticoagulated
More informationIntroduction to coagulation and laboratory tests
Introduction to coagulation and laboratory tests Marc Jacquemin Special Haemostasis Laboratory Center for Molecular and Vascular Biology University of Leuven Coagulation in a blood vessel: fibrin stabilises
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationDOACs in Non-AF Conditions: Judicious Use and Management. Kenneth A. Bauer, MD Professor of Medicine Harvard Medical School Boston, MA USA
DOACs in Non-AF Conditions: Judicious Use and Management Kenneth A. Bauer, MD Professor of Medicine Harvard Medical School Boston, MA USA Janssen rivaroxaban BMS apixaban Disclosures Daiichi Sankyo edoxaban
More informationAnticoagulation Monitoring and Reversal Strategies for Dabigatran, Rivaroxaban, and Apixaban: A Review of Clinical Effectiveness and Cost [DRAFT]
CADTH February 2012 Anticoagulation Monitoring and Reversal Strategies for Dabigatran, Rivaroxaban, and Apixaban: A Review of Clinical Effectiveness and Cost [DRAFT] Draft For Consultation: Anticoagulation
More informationA Percent Correction Formula for Evaluation of Mixing Studies
Coagulation and Transfusion Medicine / A PERCENT CORRECTION FORMULA FOR EVALUATION OF MIXING STUDIES A Percent Correction Formula for Evaluation of Mixing Studies Sheng-hsiung Chang, MD, Veronica Tillema,
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationEmergent Anticoagulation Reversal
U N C M E D I C A L C E N T E R G U I D E L I N E Emergent Anticoagulation Reversal I. PURPOSE: The purpose of these instructions is to provide guidelines for the reversal of or management of bleeding
More informationWolfgang Mueck *, Stephan Schwers and Jan Stampfuss
Mueck et al. Thrombosis Journal 2013, 11:10 REVIEW Open Access Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation
More information